Dual targeting of BCR::ABL1 and DNA methylation in advanced CML: A 3-year survival analysis of TKI-Azacitidine combination therapy

Yang Z et al. Ther Adv Hematol, August 2026 – open access publication

• Share
• Tweet
• Share
• Share